Abstract
Experience of anti-IL-1β and anti-IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
